Newcourt Acquisition Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Marc Balkin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Marc Balkin (49 yo)

2.8yrs

Permanencia

Mr. Marc Gregory Balkin has been Chief Executive Officer and Director at Newcourt Acquisition Corp since March 2021. Mr. Balkin founded of Balkin and Co in 2015. He was a Partner at Hasso Plattner Ventures...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marc Balkin	CEO & Director	2.8yrs	sin datos	sin datos
Ryan Gilbert	Member of Advisory Board	no data	sin datos	sin datos
Michael Jordaan	Chairman of the Board	2.8yrs	sin datos	sin datos
Rohit Bodas	Independent Director	2.3yrs	sin datos	sin datos
Simran Aggarwal	Independent Director	2.3yrs	sin datos	sin datos
Nicole Farb	Independent Director	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

48.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NCAC no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Newcourt Acquisition Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Newcourt Acquisition Corp Announces Resignation of Daniel Rogers as Daniel Rogers

Recent updates

Newcourt Acquisition Files Form 15

Newcourt Acquisition's Ordinary Shares, Units to Be Delisted and Deregistered Under Section 12(b) of the Exchange Act

Psyence Therapeutics Corp. completed the acquisition of Newcourt Acquisition Corp (NasdaqGM:NCAC) from Newcourt SPAC Sponsor LLC, Polar Asset Management Partners Inc. and others in a reverse merger transaction.

Newcourt Acquisition Corp announced that it expects to receive $10 million in funding from Psyence Therapeutics Corp.

Newcourt Acquisition Corp announced delayed 10-Q filing

Newcourt Acquisition Regains Compliance with the Market Value of Listed Securities Rule

Newcourt Acquisition Receives Non-Compliance Notice From Nasdaq

Newcourt Acquisition Receives Non-Compliance Notice From Nasdaq

Newcourt Acquisition Corp announced that it expects to receive $0.75 million in funding from Newcourt SPAC Sponsor LLC

Newcourt Acquisition Corp Announces Resignation of Daniel Rogers as Daniel Rogers

Psyence Therapeutics Corp. entered into a definitive business combination agreement to acquire Newcourt Acquisition Corp (NasdaqGM:NCAC) from Newcourt SPAC Sponsor LLC and others for $50 million in a reverse merger transaction.

Newcourt Acquisition Corp announced delayed annual 10-K filing

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad